DAVID W J MCGIRR
CIK 1219023 · SVP & Chief Financial Officer · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$14.30M
Companies
9
Total Filings
79
Lifetime Open-Market Net
-$10.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RYTM | Director | 11,712 | $112.84 | $1.32M | -$4.27M | 12 | 2026-06-25 |
| INSM | Director | 97,723 | $132.57 | $12.96M | -$451.5K | 16 | 2026-02-11 |
| XFOR | Director | 4,722 | $4.28 | $20.2K | $0 | 7 | 2025-06-10 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 2 | 2019-08-08 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | Director | — | $0.08 | — | $0 | 3 | 2018-06-07 |
| Roka BioScience, Inc. (ROKA) Delisted | Director | 5,000 | — | — | $180.1K | 4 | 2017-06-30 |
| Relypsa Inc (RLYP) Delisted | Director | 2,250 | — | — | -$61.9K | 5 | 2016-09-02 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | SVP & Chief Financial Officer | 23,980 | — | — | -$6.34M | 26 | 2013-02-20 |
| LIFECELL CORP (VITA) Delisted | Director | — | — | — | $0 | 1 | 2008-06-04 |
Recent Filings · Page 3 of 8
79 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-13 | INSM | Grant (A) | +14,645 | $0 | EDGAR |
| 2021-06-11 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2021-06-02 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2021-05-14 | INSM | Grant (A) | +7,558 | $0 | EDGAR |
| 2020-06-18 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2020-06-11 | XFOR | Grant (A) | — | $0 | EDGAR |
| 2020-05-14 | INSM | Grant (A) | +8,097 | $0 | EDGAR |
| 2019-08-08 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-27 | VYNE Therapeutics Inc. (MNLO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-21 | RYTM | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.